Merck and Moderna Announce Personalized Melanoma Vaccine Cuts Risk by 42 Percent

Merck and Moderna announced on Thursday that their personalized mRNA vaccine for melanoma delivered strong results in a late-stage trial. The therapy reduced the risk of death or cancer recurrence by 42 percent. This improvement was measured against standard treatment alone. The findings mark a significant step forward in how doctors treat the deadliest form of skin cancer.

The data comes from a Phase 3 trial involving 1,137 patients. All participants had stage IIB to IV melanoma. Surgeons had removed the tumors before the patients entered the study. Researchers randomized the group in a two-to-one ratio. One group received the personalized mRNA vaccine alongside standard care. The other group received only the standard treatment. That standard care consisted of Merck’s monoclonal antibody drug Keytruda.

The companies are already working with regulatory authorities to seek approval for the vaccine. They hope to bring the therapy to market soon. The full data set has been accepted for publication in the New England Journal of Medicine. This adds further weight to the findings. The trial results were originally scheduled for presentation at a major scientific conference. That event is the European Society of Medical Oncology meeting, which is currently taking place in Madrid, Spain.

The presentation was planned for Saturday. However, an oncology news site reported the results early. This broke the agreed-upon embargo on the information. Because of this, the two companies released the top-line results immediately. They had previously reported in August that the vaccine succeeded in the trial. At that time, they held back specific details until the conference data became available.

Stéphane Bancel, the CEO of Moderna, issued a statement about the outcome. He said the company believed from the start that mRNA technology could create treatments matched to specific tumors. He described the results as a defining moment for that vision. He noted that the success shows what is possible when the industry rethinks how medicines are made. He added that the findings reinforce his conviction that mRNA can fundamentally change cancer treatment.

The success of this vaccine offers broader hope for the field. It suggests that individualized cancer-targeting medicines may become a new standard. Many researchers and patients have watched these developments closely. The trial results provide concrete evidence for this approach. The collaboration between Merck and Moderna continues to shape the future of oncology. Both firms remain focused on getting the therapy approved and available to those who need it.